NASDAQ:GMAB

Genmab A/S (GMAB) Stock Forecast, Price & News

$36.08

-0.41 (-1.12%)

(As of 09/22/2023 ET)

Compare

Today's Range: $35.98
▼
$36.42
50-Day Range: $36.07
▼
$42.25
52-Week Range: $31.40
▼
$47.50

Volume: 315,497 shs
Average Volume: 382,735 shs
Market Capitalization: $23.83 billion

P/E Ratio: 36.08
Dividend Yield: N/A
Price Target: $41.40

Genmab A/S MarketRank™ Forecast

Analyst Rating: Hold
2.27 Rating Score
Upside/Downside: 14.7% Upside
$41.40 Price Target
Short Interest: Healthy
0.44% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 17.65%
From $1.02 to $1.20 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

137th out of 969 stocks

Pharmaceutical Preparations Industry

42nd out of 440 stocks

3.1

Analyst's Opinion

Consensus Rating
Genmab A/S has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 6 buy ratings, 7 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.40, Genmab A/S has a forecasted upside of 14.7% from its current price of $36.08.
Amount of Analyst Coverage
Genmab A/S has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
0.44% of the outstanding shares of Genmab A/S have been sold short.
Short Interest Ratio / Days to Cover
Genmab A/S has a short interest ratio ("days to cover") of 6.
Change versus previous month
Short interest in Genmab A/S has recently decreased by 16.23%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Genmab A/S does not currently pay a dividend.
Dividend Growth
Genmab A/S does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GMAB.

0.0

News and Social Media Coverage

Search Interest
Only 3 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genmab A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.54% of the stock of Genmab A/S is held by insiders.
Percentage Held by Institutions
Only 6.29% of the stock of Genmab A/S is held by institutions.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Genmab A/S are expected to grow by 17.65% in the coming year, from $1.02 to $1.20 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Genmab A/S is 36.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.12.
Price to Earnings Ratio vs. Sector
The P/E ratio of Genmab A/S is 36.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 143.29.
Price to Earnings Growth Ratio
Genmab A/S has a PEG Ratio of 2.17. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Genmab A/S has a P/B Ratio of 6.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Genmab A/S (NASDAQ:GMAB) Stock

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GMAB Price History

30 days | 90 days | 365 days | Advanced Chart

GMAB Stock News Headlines

September 5, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Genmab (GMAB)

September 5, 2023 | markets.businessinsider.com

Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications

September 24, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 5, 2023 | finance.yahoo.com

Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals

September 5, 2023 | finance.yahoo.com

Why Shares of Zai Lab Limited Were Jumping on Tuesday

September 4, 2023 | reuters.com

Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint

August 31, 2023 | msn.com

Denmark stocks lower at close of trade; OMX Copenhagen 20 down 1.55%

August 30, 2023 | seekingalpha.com

Genmab Is Down To Attractive Levels

September 24, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

August 15, 2023 | markets.businessinsider.com

Analyst Expectations for Genmab's Future

August 9, 2023 | markets.businessinsider.com

Genmab (GMAB) Receives a Buy from Truist Financial

July 28, 2023 | finanznachrichten.de

Genmab A/S: Genmab Updates 2023 Financial Guidance

July 28, 2023 | seekingalpha.com

Genmab raises FY 2023 guidance on back of Darzalex sales

July 24, 2023 | markets.businessinsider.com

12 Analysts Have This to Say About Genmab

July 21, 2023 | finance.yahoo.com

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

July 20, 2023 | finanznachrichten.de

Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2023

July 20, 2023 | finance.yahoo.com

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023

July 17, 2023 | msn.com

Denmark stocks higher at close of trade; OMX Copenhagen 20 up 0.46%

July 14, 2023 | markets.businessinsider.com

Morgan Stanley Keeps Their Sell Rating on Genmab (GMAB)

July 7, 2023 | msn.com

Denmark stocks lower at close of trade; OMX Copenhagen 20 down 0.41%

June 29, 2023 | seekingalpha.com

Genmab: Epkinly's Approval Not Big Enough Needle-Mover (Neutral)

June 27, 2023 | marketwatch.com

AbbVie, Genmab Need Further Follow Up on Trial for Follicular Lymphoma Treatment

June 27, 2023 | tmcnet.com

Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab

June 27, 2023 | nasdaq.com

AbbVie Announces Positive Results From Phase 1/2 Trial Of Epcoritamab In R/R Follicular Lymphoma

June 21, 2023 | finanznachrichten.de

Nasdaq Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise

June 20, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX), Genmab (GMAB) and Immunocore Holdings (IMCR)

June 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Inspire Medical Systems (INSP) and Genmab (GMAB)

See More Headlines

Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GMAB Company Calendar

Last Earnings: 8/03/2023
Today: 9/23/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GMAB
CUSIP: N/A
CIK: 1434265
Web: www.genmab.com
Phone: (457) 020-2728
Fax: N/A
Employees: 1,660
Year Founded: 1999

Price Target and Rating

Average Stock Price Forecast: $41.40
High Stock Price Forecast: $54.00
Low Stock Price Forecast: $23.00
Forecasted Upside/Downside: +14.7%
Consensus Rating: Hold
Rating Score (0-4): 2.27
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.00
Trailing P/E Ratio: 36.08
Forward P/E Ratio: 35.37
P/E Growth: 2.17
Net Income: $781.91 million
Net Margins: 28.78%
Pretax Margin: 36.62%
Return on Equity: 16.93%
Return on Assets: 15.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.93
Quick Ratio: 14.90

Sales & Book Value

Annual Sales: $2.07 billion
Price / Sales: 11.53
Cash Flow: $1.25 per share
Price / Cash Flow: 28.89
Book Value: $5.89 per share
Price / Book: 6.13

Miscellaneous

Outstanding Shares: 660,570,000
Free Float: 650,398,000
Market Cap: $23.83 billion
Optionable: Not Optionable
Beta: 0.94

Social Links

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Jan G.J. van de Winkel Ph.D. (Age 62)
Co-Founder, Pres & CEO
Comp: $2.71M

Mr. Anthony Pagano (Age 45)
Exec. VP & CFO
Comp: $1.01M

Mr. Anthony Mancini (Age 52)
Exec. VP & COO
Comp: $1.1M

Mr. Martin Schultz (Age 47)
Sr. Director of Clinical Operations & Non-Independent Director
Comp: $72.04k

Dr. Judith V. Klimovsky M.D. (Age 65)
Exec. VP & Chief Devel. Officer
Comp: $1.14M

Dr. Tahamtan Ahmadi (Age 50)
Exec. VP, Chief Medical Officer & Head of Experimental Medicines
Comp: $1.08M

Dr. Mijke Zachariasse Ph.D. (Age 49)
Sr. Director, Head of Antibody Research Materials & Non-Independent Director
Comp: $144.08k

Mr. Takahiro Hamatani (Age 48)
Sr. Director of Fin. Japan & Non-Independent Director
Comp: $72.04k

Mr. Andrew Carlsen
Sr. Director, VP & Head of Investor Relations

Ms. Birgitte Stephensen M.Sc. (Age 62)
Exec. VP & Chief Legal Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GMAB Stock - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings or view top-rated stocks.
What is Genmab A/S's stock price forecast for 2023?: 15 equities research analysts have issued 1-year price targets for Genmab A/S's stock. Their GMAB share price forecasts range from $23.00 to $54.00. On average, they predict the company's stock price to reach $41.40 in the next year. This suggests a possible upside of 14.7% from the stock's current price.
View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts.
How have GMAB shares performed in 2023?: Genmab A/S's stock was trading at $42.38 at the beginning of the year. Since then, GMAB stock has decreased by 14.9% and is now trading at $36.08.
View the best growth stocks for 2023 here.
Are investors shorting Genmab A/S?: Genmab A/S saw a drop in short interest in August. As of August 31st, there was short interest totaling 2,890,000 shares, a drop of 16.2% from the August 15th total of 3,450,000 shares. Based on an average daily volume of 485,500 shares, the days-to-cover ratio is presently 6.0 days.
View Genmab A/S's Short Interest.
When is Genmab A/S's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our GMAB earnings forecast.
How were Genmab A/S's earnings last quarter?: Genmab A/S (NASDAQ:GMAB) issued its quarterly earnings results on Thursday, August, 3rd. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by $0.01. The business earned $613.43 million during the quarter, compared to the consensus estimate of $618.77 million. Genmab A/S had a trailing twelve-month return on equity of 16.93% and a net margin of 28.78%.
What ETFs hold Genmab A/S's stock?: ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Goldman Sachs Future Health Care Equity ETF (GDOC), B.A.D. Etf (BAD), Range Cancer Therapeutics ETF (CNCR) and WisdomTree BioRevolution Fund (WDNA).ActivePassive International Equity ETF (APIE).
What guidance has Genmab A/S issued on next quarter's earnings?: Genmab A/S issued an update on its FY 2023 earnings guidance on Friday, July, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.27 billion-$2.41 billion, compared to the consensus revenue estimate of $2.38 billion.

What other stocks do shareholders of Genmab A/S own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).
When did Genmab A/S IPO?: (GMAB) raised $503 million in an IPO on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.
What is Genmab A/S's stock symbol?: Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB."
Who are Genmab A/S's major shareholders?: Genmab A/S's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (1.24%), BlackRock Inc. (0.79%), Capital International Investors (0.64%), Renaissance Technologies LLC (0.13%), Stifel Financial Corp (0.11%) and Royal Bank of Canada (0.11%).
How do I buy shares of Genmab A/S?: Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Genmab A/S's stock price today?: One share of GMAB stock can currently be purchased for approximately $36.08.
How much money does Genmab A/S make?: Genmab A/S (NASDAQ:GMAB) has a market capitalization of $23.83 billion and generates $2.07 billion in revenue each year. The company earns $781.91 million in net income (profit) each year or $1.00 on an earnings per share basis.
How many employees does Genmab A/S have?: The company employs 1,660 workers across the globe.
How can I contact Genmab A/S?: Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728 or via email at acn@genmab.com.

This page (NASDAQ:GMAB) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial